(November 20, 2015) A study published in BMC Cancer demonstrates that ovarian cancer patients who had a history of oral contraceptive use had better outcomes than those who had not previously used them. Dr. Aminah Jatoi and co-author Dr. Ellen Goode, both of the Mayo Clinic, examined 1,398 cases during a thirteen year period and … Continued
(Nov. 19, 2016) In research published this month in Gynecologic Oncology, a group of Canadian researchers have found that long-term survival is not associated with BRCA mutation status in ovarian cancer patients. Past research has shown that after a diagnosis of ovarian cancer, positive BRCA mutation status confers a mortality benefit that diminishes with time. In … Continued
OCRF has awarded $5.2 million in new grants, bringing our total investment in ovarian cancer research to nearly $70 million.
A new study of ovarian cancer cells from the University of Michigan Comprehensive Cancer Center, funded in part by an OCRF grant to Dr. Weiping Zou, reveals molecular changes within the tumor that prevent immunotherapy drugs from killing off the cancer. The research was published in Nature. Immunotherapy treatments have proven wildly successful in treating … Continued
Earlier this month, we attended the AACR conference Advances in Ovarian Cancer Research: Exploiting Vulnerabilities, which highlighted many recent pre-clinical advancements in the treatment of ovarian cancer. Much of the work presented was hot off the presses and unpublished – so we were asked not to share too many details from the work publicly. To … Continued
In January’s State of the Union Address, President Obama ushered in an exciting phase in new medical research by introducing the Precision Medicine Initiative (PMI). This initiative will expand our understanding of personalized medicine, when doctors pick treatments to suit individual patients rather than the ‘one-size-fits-all’ approach. Since January, the President’s advisers have begun to … Continued
(October 15, 2015) According to a Japanese study published in Cancer, BRCA1/2 gene mutations may be associated with an inherited risk of ovarian cancer regardless of family history. The researchers examined 95 women with ovarian cancer who were treated from 2013 to 2015. BRCA1/2 gene mutation tests were performed with next-generation sequencing in order to determine a link … Continued
(October 7, 2015) A report published in JAMA Oncology shows that most commercially insured women who underwent BRCA genetic testing did not receive genetic counseling by trained genetics professionals. Lack of clinician recommendation was the most commonly reported reason why they didn’t receive genetic counseling. The study authors examined the factors associated with use of … Continued
(October 1, 2015) A new study published in the Journal of Clinical Oncology shows that women with the most common type of ovarian cancer can safely take hormone replacement therapy (HRT), and it could have a beneficial effect on their survival. The 24-year, phase III international trial provides the strongest evidence yet that women with … Continued
By Annie Ellis: On September 3, 2015, Ovarian cancer survivors and FDA Patient Representatives Peg Ford, Susan Leighton and Annie Ellis were invited to provide the patient perspective at the recent Ovarian Cancer Endpoints Workshop hosted by the Food and Drug Administration (FDA). This meeting was co-sponsored by the Society of Gynecologic Oncology (SGO), the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). Click plus sign to read more.
By Annie Ellis On September 3, 2015, Ovarian cancer survivors and FDA Patient Representatives Peg Ford, Susan Leighton and Annie Ellis were invited to provide the patient perspective at the recent Ovarian Cancer Endpoints Workshop hosted by the Food and Drug Administration (FDA). This meeting was co-sponsored by the Society of Gynecologic Oncology (SGO), the … Continued
(September 21, 2015) A small study found that treatment with the anti-PD-1 immunotherapy nivolumab was able to produce complete responses in patients with advanced platinum-resistant ovarian cancer. The phase II study of 20 patients had an overall response rate of 15% (3 responders); an additional 6 patients had stable disease. The median progression-free survival time … Continued
Get email updates about research news, action alerts, and ways to join the fight.
